2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM)

Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).

Metastatic Pancreatic Adenocarcinoma

10.1200/jco.2016.34.15_suppl.4120 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4120-4120

Author(s):

Pascal Hammel ◽

Jean Baptiste Bachet ◽

Jérôme Desramé ◽

Aurelia Meurisse ◽

Benoist Chibaudel ◽

...

Keyword(s):

Pancreatic Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

BMC Cancer ◽

10.1186/s12885-015-1656-4 ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 4

Author(s):

Jean-Baptiste Bachet ◽

◽

Benoist Chibaudel ◽

Franck Bonnetain ◽

Pierre Validire ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Pancreatic Cancer ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Biomarkers for immunotherapy: Results from the analysis of an HLA-status double-blind, biologically randomized phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as first-line therapy for advanced colorectal cancer (FXV study).

10.1200/jco.2014.32.15_suppl.3038 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 3038-3038

Author(s):

Shoichi Hazama ◽

Yusuke Nakamura ◽

Hiroaki Tanaka ◽

Ko Tahara ◽

Ryoichi Shimizu ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Study ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.

10.1200/jco.2018.36.15_suppl.tps4142 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS4142-TPS4142 ◽

Cited By ~ 3

Author(s):

Vaibhav Sahai ◽

Kent A. Griffith ◽

Muhammad Shaalan Beg ◽

Mark Zalupski

Keyword(s):

Biliary Tract ◽

Phase Ii ◽

Biliary Tract Cancer ◽

Phase Ii Study ◽

First Line ◽

Tract Cancer ◽

First Line Therapy ◽

Line Therapy ◽

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2300 ◽

2020 ◽

Vol 31 ◽

pp. S1195

Author(s):

D.J. Renouf ◽

J.J. Knox ◽

P. Kavan ◽

D. Jonker ◽

S. Welch ◽

...

Keyword(s):

Pancreatic Ductal Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Ductal Adenocarcinoma ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Cancer Trials

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdm474 ◽

2008 ◽

Vol 19 (2) ◽

pp. 362-369 ◽

Cited By ~ 195

Author(s):

R. Rosell ◽

G. Robinet ◽

A. Szczesna ◽

R. Ramlau ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Annals of Oncology ◽

10.1093/annonc/mdt028 ◽

2013 ◽

Vol 24 (6) ◽

pp. 1580-1587 ◽

Cited By ~ 38

Author(s):

W. Schmiegel ◽

A. Reinacher-Schick ◽

D. Arnold ◽

S. Kubicka ◽

W. Freier ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Study Group ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: a randomized phase‐II study ‐ the PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO ‐0510

International Journal of Cancer ◽

10.1002/ijc.33864 ◽

2021 ◽

Author(s):

Anica Högner ◽

Salah‐Eddin Al‐Batran ◽

Jens T. Siveke ◽

Mario Lorenz ◽

Prisca Bartels ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

10.1200/jco.2010.28.15_suppl.7603 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7603-7603 ◽

Cited By ~ 6

Author(s):

G. K. Dy ◽

S. J. Mandrekar ◽

G. D. Nelson ◽

H. J. Ross ◽

R. H. Ansari ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers

Archives of Medical Science ◽

10.5114/aoms.2014.44862 ◽

2014 ◽

Vol 4 ◽

pp. 717-724 ◽

Cited By ~ 2

Author(s):

Ke-Jun Liu ◽

Zhong-Zhen Guan ◽

Ying Liang ◽

Xu-Qing Yang ◽

Jin Peng ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Lung Cancers ◽

First Line Therapy ◽

Line Therapy ◽